Repotrectinib

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 108 publications

Secretory Breast Carcinoma in A Six-Year-Old Girl: Case Report With Genetic Insights and Therapeutic Implications.

Secretory Breast Carcinoma in A Six-Year-Old Girl: Case Report With Genetic Insights and Therapeutic Implications.

Journal: Balkan journal of medical genetics : BJMG

Published: May 18, 2026

Phase Ib of repotrectinib plus osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer.

Phase Ib of repotrectinib plus osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: March 23, 2026

Glioblastoma, IDH-wildtype, with a novel MEF2D-NTRK1 gene fusion: a case report.

Glioblastoma, IDH-wildtype, with a novel MEF2D-NTRK1 gene fusion: a case report.

Journal: Frontiers in oncology

Published: March 18, 2026

Toxicity of NTRK inhibitors: A clinical overview.

Toxicity of NTRK inhibitors: A clinical overview.

Journal: Bulletin du cancer

Published: February 22, 2026

Repotrectinib is a next-generation TKI for NTRK fusion-positive solid tumours.

Repotrectinib is a next-generation TKI for NTRK fusion-positive solid tumours.

Journal: Nature reviews. Clinical oncology

Published: February 18, 2026

Case report: successful use of repotrectinib in a ROS1 fusion-positive lung adenocarcinoma patient with severe renal insufficiency and prior tyrosine kinase inhibitor treatment failure.

Case report: successful use of repotrectinib in a ROS1 fusion-positive lung adenocarcinoma patient with severe renal insufficiency and prior tyrosine kinase inhibitor treatment failure.

Journal: Anti-cancer drugs

Published: February 11, 2026

Effectiveness and cost-effectiveness of first-line versus second-line use of repotrectinib in the treatment of ROS1 fusion-positive advanced NSCLC.

Effectiveness and cost-effectiveness of first-line versus second-line use of repotrectinib in the treatment of ROS1 fusion-positive advanced NSCLC.

Journal: Expert review of anticancer therapy

Published: January 09, 2026

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; encorafenib for colorectal cancer, daratumumab for multiple myeloma, repotrectinib for NTRK-fusion positive solid tumors, and venetoclax for leukemia.

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; encorafenib for colorectal cancer, daratumumab for multiple myeloma, repotrectinib for NTRK-fusion positive solid tumors, and venetoclax for leukemia.

Journal: International journal of clinical oncology

Published: December 15, 2025

Rare but not forgotten: Therapeutic advancements for rare childhood cancers.

Rare but not forgotten: Therapeutic advancements for rare childhood cancers.

Journal: Molecular therapy. Oncology

Published: December 01, 2025

Lorlatinib in Tyrosine Kinase Inhibitor-Naive Advanced ROS1-Positive Non-Small Cell Lung Cancer: A Phase 2 Nonrandomized Clinical Trial.

Lorlatinib in Tyrosine Kinase Inhibitor-Naive Advanced ROS1-Positive Non-Small Cell Lung Cancer: A Phase 2 Nonrandomized Clinical Trial.

Journal: JAMA oncology

Published: November 26, 2025

Corticosteroids for Managing TRK Inhibitor Withdrawal Pain: A Report on Two Cases.

Corticosteroids for Managing TRK Inhibitor Withdrawal Pain: A Report on Two Cases.

Journal: Current oncology (Toronto, Ont.)

Published: November 18, 2025

Three novel concomitant NTRK2 fusions in medullary thyroid carcinoma with diagnostic implications.

Three novel concomitant NTRK2 fusions in medullary thyroid carcinoma with diagnostic implications.

Journal: Discover oncology

Published: November 06, 2025

Showing 1-12 of 108

Last Updated: 06/30/2026